Diffusion Pharmaceuticals Announces Validation of European Patent for Oral Formulations of TSC

- June 12th, 2018

Diffusion Pharmaceuticals (NASDAQ:DFFN) a clinical-stage biotechnology company focused on extending the life expectancy of cancer patients, today announced the validation of European Patent No.: 2 575 487, entitled “Oral Formulations of Bipolar Trans Carotenoids.” As quoted in the press release: This patent is directed to oral formulations of bipolar trans carotenoids including trans sodium crocetinate … Continued

Diffusion Pharmaceuticals (NASDAQ:DFFN) a clinical-stage biotechnology company focused on extending the life expectancy of cancer patients, today announced the validation of European Patent No.: 2 575 487, entitled “Oral Formulations of Bipolar Trans Carotenoids.”

As quoted in the press release:

This patent is directed to oral formulations of bipolar trans carotenoids including trans sodium crocetinate (“TSC”). Embodiments of the invention include the novel compositions in the form of a tablet, pill or capsule. The claims also include compositions for the treatment of hypoxia caused by many disorders. This European Patent is based on the same patent application that was allowed by the U.S. Patent and Trademark Office (PTO) in January 2018.

Click here to read the full press release.

Are You Aware of the FDA's Plans for 2018?

Find out what's going on in our new report
 

Leave a Reply

Your email address will not be published. Required fields are marked *